Soleus Capital Management’s AbbVie ABBV Stock Holding History

Soleus Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,750	Closed	-$3.11M	–	82
2024 Q3	$3.11M	Buy	+15,750	New	+$2.94M	0.24%	71
2024 Q1	–	Sell	-14,800	Closed	-$2.29M	–	92
2023 Q4	$2.29M	Buy	+14,800	New	+$2.16M	0.25%	54
2022 Q1	–	Sell	-27,500	Closed	-$3.72M	–	66
2021 Q4	$3.72M	Buy	+27,500	New	+$3.25M	0.37%	44
2021 Q1	–	Sell	-21,477	Closed	-$2.3M	–	73
2020 Q4	$2.3M	Buy	+21,477	New	+$2.06M	0.3%	36
2020 Q3	–	Sell	-28,900	Closed	-$2.84M	–	64
2020 Q2	$2.84M	Buy	28,900 +2,400	+9%	+$211K	1.62%	22
2020 Q1	$2.02M	Buy	+26,500	New	+$2.26M	2.35%	17

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Soleus Capital Management's ABBV Position: Q4 2024 in Review

Soleus Capital Management sold out of AbbVie (ABBV) in Q4 2024, closing a stake of 15,750 shares — an estimated $3.11M sold.

Soleus Capital Management first reported a position in ABBV in Q1 2020 and held it in 6 quarters. The position peaked at $3.72M in Q4 2021. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

Soleus Capital Management reported no remaining AbbVie position as of Q4 2024 after selling out during the quarter.
Soleus Capital Management sold 15,750 AbbVie shares in Q4 2024, an estimated $3.11M.
Soleus Capital Management first reported a position in AbbVie in Q1 2020 and held it in 6 quarters.
Soleus Capital Management's AbbVie position peaked at $3.72M in Q4 2021.
3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.